Recommendation
No—do not use doxycycline as first-line for pneumonic plague; use a fluoroquinolone (ciprofloxacin, levofloxacin, or moxifloxacin) or an aminoglycoside (gentamicin or streptomycin), reserving doxycycline only as an alternative. 1
Evidence basis (prioritizing morbidity, mortality, QOL)
- Guideline (CDC/US HHS 2021): For adults with pneumonic plague, first-line therapy is a fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin) or an aminoglycoside (gentamicin, streptomycin); doxycycline is listed only as an alternative, with notes of reduced efficacy in pneumonic disease. Duration 10–14 days. Use dual therapy initially if severe disease or suspected engineered resistance; otherwise monotherapy is acceptable once improving 1.
- Rationale and nuance:
- Animal models show doxycycline is ineffective for pneumonic plague treatment compared with ciprofloxacin, supporting its non–first-line status for lung infection, which directly impacts mortality and QOL 2, 3.
- Doxycycline is first-line for bubonic/pharyngeal plague, but that does not extend to pneumonic disease due to lower observed efficacy in lungs 1.
- Drug label: Doxycycline is FDA-indicated for plague due to Yersinia pestis, but the label does not specify pneumonic as first-line; guideline positioning remains alternative for pneumonic disease to optimize survival 4.
Practical algorithm (adult, otherwise healthy)
- If suspected or confirmed pneumonic plague:
- Start immediately with one of:
- Ciprofloxacin 400 mg IV q8h or 750 mg PO q12h, or
- Levofloxacin 750 mg IV/PO q24h, or
- Moxifloxacin 400 mg IV/PO q24h, or
- Gentamicin 5 mg/kg IV/IM q24h, or
- Streptomycin 1 g IV/IM q12h
- Choose fluoroquinolone if concomitant CAP coverage is needed; excellent lung penetration supports mortality benefit 1.
- Severe disease or concern for engineered resistance: initiate dual therapy with two classes, then narrow when clinically improved 1.
- Treat 10–14 days 1.
- Start immediately with one of:
- Use doxycycline only if first-line agents are contraindicated/unavailable:
- Doxycycline 200 mg loading dose, then 100 mg IV/PO q12h (10–14 days) 1.
- Reassess rapidly with susceptibility data; resistance is rare but possible—ensure prompt AST if clinical response is suboptimal 1, 5.
Pitfalls and caveats
- Do not rely on doxycycline as initial monotherapy for pneumonic plague—animal data and guideline hierarchy indicate lower efficacy in lungs, risking higher mortality 1, 2, 3.
- Delay in effective therapy (>24 hours from symptom onset) markedly worsens outcomes; start guideline-preferred agents immediately to reduce mortality 5.
- If diagnosis uncertain, prefer levofloxacin or moxifloxacin to cover typical/atypical CAP pathogens while treating plague, improving QOL and survival 1.